|
|
|
|
|
|
|
|
|
|
Abstract
Objective
The
aim of the study was to examine whether comorbidity is an independent
prognostic factor for 3129 women diagnosed with ovarian cancer from 2005
to 2011. As Performance status (PS) might capture the impact of
comorbidity we addressed whether comorbidity can be explained by PS or
whether comorbidity has an independent impact on survival.
Methods
The
Danish Gynecological Cancer Database (DGCD) is a national clinical
database including information on comorbidity and a large number of
tumor-related and patient-related factors.
The Charlson Comorbidity Index was used to measure the patients' comorbidity based on the registration in DGCD. The overall mortality (OS) from the date of surgery to death or censoring was the outcome measure.
The Charlson Comorbidity Index was used to measure the patients' comorbidity based on the registration in DGCD. The overall mortality (OS) from the date of surgery to death or censoring was the outcome measure.
Results
The
hazard ratio (HR) for patients with comorbidity was 3.31 (1.14–1.50)
compared to patients without comorbidity after adjustment for age,
stage, residual tumor, histology and grade. After including PS in the
model, comorbidity remained significant for OS. Age, stage, residual
tumor, histology and PS prove to be independent prognostic factors as
well. No association is found between comorbidity and receiving surgery
or not.
Conclusion
Comorbidity
is an independent prognostic factor, and has a negative impact on the
survival of ovarian cancer patients. However, comorbidity has a smaller
impact on survival compared with the other prognostic factors
considered.
Highlights
► Comorbidity is an independent prognostic factor
► PS attenuates the impact of impact of comorbidity
► PS attenuates the impact of impact of comorbidity
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.